Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Mepolizumab (COPD) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A26-25
Last updated

Report documents

  1. Extract of dossier assessment

    Mepolizumab (COPD) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 150 kB, DE, not accessible
    Download file : Extract of dossier assessment (PDF document, 150 kB, DE, not accessible)

  2. Dossier assessment

    Mepolizumab (COPD) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 483 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A26-25
    Download file : Dossier assessment (PDF document, 483 kB, DE, not accessible)

Drug assessment at a glance

  1. Drug assessment at a glance

    Mepolizumab (COPD) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 201 kB, EN, not accessible
    Download file : Drug assessment at a glance (PDF document, 201 kB, EN, not accessible)

Dossier assessment

Indication:

Add-on maintenance treatment in adults for uncontrolled COPD characterized by raised blood eosinophils on a combination of an inhaled corticosteroid, a long-acting beta-2 sympathomimetic, and a long-acting muscarinic antagonist

Result of dossier assessment:

Added benefit not proven

Project details

Project no.
A26-25
Commission
Commission awarded on 09.03.2026 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Airways and respiratory system
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A26-25

Connected Projects

  1. Dossier assessment

    Mepolizumab - Benefit assessment according to §35a Social Code Book V

    Project no.
    A16-03
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Mepolizumab (asthma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A18-58
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Mepolizumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-150
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Mepolizumab (eosinophilic granulomatosis with polyangiitis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-151
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Mepolizumab (hypereosinophilic syndrome) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-152
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page